Movatterモバイル変換

[0]ホーム
URL:

Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
Thehttps:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

NIH NLM Logo
Log inShow account info
Access keysNCBI HomepageMyNCBI HomepageMain ContentMain Navigation
pubmed logo
Advanced Clipboard
User Guide

Full text links

Springer full text link Springer Free PMC article
Full text links

Actions

Share

Randomized Controlled Trial
.2021 Sep;77(9):1323-1331.
doi: 10.1007/s00228-021-03122-z. Epub 2021 Mar 22.

Sertraline concentrations in pregnant women are steady and the drug transfer to their infants is low

Affiliations
Randomized Controlled Trial

Sertraline concentrations in pregnant women are steady and the drug transfer to their infants is low

E Heinonen et al. Eur J Clin Pharmacol.2021 Sep.

Abstract

Purpose: Sertraline, a selective serotonin reuptake inhibitor (SSRI), is one of the most commonly used antidepressant during pregnancy. Plasma sertraline concentrations vary markedly between individuals, partly explained by variability in hepatic drug metabolizing cytochrome P450-enzyme activity. Our purpose was to study the variability in the plasma concentrations in pregnant women and the passage to their infants.

Method: Pregnant women with moderate untreated depression were recruited in 2016-2019 in Stockholm Region and randomized to treatment with sertraline or placebo. All received Internet-based cognitive behavior therapy as non-medical treatment. Sertraline plasma concentrations were measured around pregnancy weeks 21 and 30, at delivery, 1-month postpartum, in cord blood and at 48 h of age in the infant. The clinical course of the infants was followed.

Results: Nine mothers and 7 infants were included in the analysis. Median dose-adjusted sertraline concentration in second trimester was 0.15(ng/mL) /(mg/day), in third trimester and at delivery 0.19 and 1-month postpartum 0.25, with a 67% relative difference between second trimester and postpartum. The interindividual variation was 10-fold. Median concentrations in the infants were 33% and 25% of their mothers', measured in cord blood, and infant plasma, respectively. Only mild and transient adverse effects were seen on the infants.

Conclusion: Placental passage of sertraline to the infant is low. However, the interindividual variation in maternal concentrations during pregnancy is huge, why therapeutic drug monitoring might assist in finding the poor metabolizers at risk for adversity and increase the safety of the treatment.

Trial registration: The trial was registered at clinicaltrials.gov July 9, 2014 with TRN:NCT02185547.

Keywords: Antenatal depression; Infant; Pharmacokinetics; Pregnancy; Selective serotonin reuptake inhibitors; Therapeutic drug monitoring.

© 2021. The Author(s).

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
a, b Boxplots of the penetration ratios of sertraline (a) and desmethylsertraline (b).a) Penetration ratio of sertraline into cord blood (CB/MP, 5 mother-infant pairs): median 0.33; IQ-range 0.24–0.58; range: 0.14–1.17, and infant plasma (IP/MP, 5 mother-infant pairs): median 0.25; IQ-range 0.23–0.26; range 0.16–0.49.b) Penetration ratio of desmethylsertraline into cord blood (CB/MP, 5 mother-infant pairs): median 0.29; IQ-range 0.28–0.36; range: 0.24–1.42, and infant plasma (IP/MP, 5 mother-infant pairs); median 0.34, IQ-range 0.31–0.37; range 0.31–0.46
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Molenaar NM, Bais B, Lambregtse-Van Den Berg MP, Mulder CL, Howell EA, Fox NS, Rommel A-S, Bergink V, Kamperman AM. The international prevalence of antidepressant use before, during, and after pregnancy: a systematic review and meta-analysis of timing, type of prescriptions and geographical variability. J Affect Disord. 2020;264:82–89. doi: 10.1016/j.jad.2019.12.014. - DOI - PubMed
    1. Reefhuis J, Devine O, Friedman JM, Louik C, Honein MA, National Birth Defects Prevention S Specific SSRIs and birth defects: Bayesian analysis to interpret new data in the context of previous reports. BMJ. 2015;351:h3190. doi: 10.1136/bmj.h3190. - DOI - PMC - PubMed
    1. Reis M, Kallen B. Delivery outcome after maternal use of antidepressant drugs in pregnancy: an update using Swedish data. Psychol Med. 2010;40(10):1723–1733. doi: 10.1017/S0033291709992194. - DOI - PubMed
    1. Womersley K, Ripullone K, Agius M. What are the risks associated with different selective serotonin re-uptake inhibitors (SSRIs) to treat depression and anxiety in pregnancy? An evaluation of current evidence. Psychiatr Danub. 2017;29(Suppl 3):629–644. - PubMed
    1. Sujan AC, Rickert ME, Oberg AS, Quinn PD, Hernandez-Diaz S, Almqvist C, Lichtenstein P, Larsson H, D'Onofrio BM. Associations of maternal antidepressant use during the first trimester of pregnancy with preterm birth, small for gestational age, autism spectrum disorder, and attention-deficit/hyperactivity disorder in offspring. JAMA. 2017;317(15):1553–1562. doi: 10.1001/jama.2017.3413. - DOI - PMC - PubMed

Publication types

MeSH terms

Substances

Associated data

Related information

Grants and funding

LinkOut - more resources

Full text links
Springer full text link Springer Free PMC article
Cite
Send To

NCBI Literature Resources

MeSHPMCBookshelfDisclaimer

The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.

[8]ページ先頭
©2009-2025 Movatter.jp